Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1018 ISS
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
**1018 ISS** is a synthetic phosphorothioate CpG oligodeoxynucleotide developed by Dynavax as an innate immune stimulant. It activates **Toll-like receptor 9**, promoting dendritic-cell maturation, type I interferon-associated immune activation, cytokine production, antigen presentation, and T-helper-1-skewed immune responses. In a Phase 2 study for relapsed or refractory CD20-positive B-cell follicular lymphoma, subcutaneous 1018 ISS was administered following rituximab to augment rituximab-mediated antibody-dependent cellular cytotoxicity and reshape the tumor immune microenvironment. The follicular lymphoma program was investigational and has not resulted in an approved oncology indication.
- Other names
- CpG 1018CpG1018CpG-1018CpG oligodeoxynucleotide 1018ISS 1018ISS1018ISS-1018
02
Targets
CD20 (B-lymphocyte antigen CD20)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on 1018 ISS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1018 ISS.